Ethinylestradiol indications
Oral
Menopausal hormone replacement therapy
Adult: In menopausal women: 10-20 mcg daily in conjunction with a progestogen in women with uterus.
Oral
Female hypogonadism
Adult: 10-50 mcg daily in a cyclical regimen.
Oral
Palliative treatment of breast carcinoma
Adult: In postmenopausal women: 0.1-1 mg tid.
Oral
Palliative treatment of prostatic carcinoma
Adult: 0.15-3 mg daily.
Oral
As part of combined oral contraceptive
Adult: As the oestrogenic component of combined oral contraceptive: 20-40 mcg/day.
Ethinylestradiol description
Generally refers to the 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Ethinylestradiol-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Various isomers can be synthesized.
Ethinylestradiol dosage
Oral
Menopausal hormone replacement therapy
Adult: In menopausal women: 10-20 mcg daily in conjunction with a progestogen in women with uterus.
Oral
Female hypogonadism
Adult: 10-50 mcg daily in a cyclical regimen.
Oral
Palliative treatment of breast carcinoma
Adult: In postmenopausal women: 0.1-1 mg tid.
Oral
Palliative treatment of prostatic carcinoma
Adult: 0.15-3 mg daily.
Oral
As part of combined oral contraceptive
Adult: As the oestrogenic component of combined oral contraceptive: 20-40 mcg/day.
Ethinylestradiol interactions
Concurrent use with hepatic enzyme inducers e.g. barbiturates, primidone, phenobarbitone, phenytoin, phenylbutazone, rifampicin, carbamazepine and griseofulvin may affect contraceptive efficacy. Short courses of broad-spectrum antibiotics may also reduce the efficacy of the oral contraceptive. Concurrent use with HIV protease and non-nucleoside reverse transcriptase inhibitors may affect hepatic metabolism of gestodene and/or Ethinylestradiol. May increase plasma concentrations of ciclosporin and decrease the serum levels of lamotrigine. Concurrent use with felbamate may increase the clearance of gestodene. Gestodene may increase serum levels of buprenorphine. Co-trimoxazole, miconazole and etoricoxib may increase serum levels of Ethinylestradiol. Aprepitant, modafinil and bosentan may reduce the serum levels of Ethinylestradiol. Metabolism of omeprazole may be inhibited by Ethinylestradiol. GI absorption of Ethinylestradiol may be increased by concurrent admin of paracetamol.
Food Interaction
Concurrent treatment with St John’s wort may reduce efficacy of the oral contraceptive.
Ethinylestradiol side effects
Menstrual irregularities; headache, dizziness; breast discomfort; gynaecomastia; depression; disturbance of appetite; wt changes; fluid retention; oedema; changes in libido; hair loss or hirsutism; GI disturbances (nausea and vomiting); genitourinary changes; haematologic disorders; endocrine and metabolic disorders; cholestatic jaundice; local skin reactions; chorea; contact lens intolerance; steeping of corneal curvature; pulmonary thromboembolism; carbohydrate and/or glucose intolerance; depression; chloasma; BP increase, liver impairment; reduced menstrual loss, ’spotting’ in early cycles, absence of withdrawal bleeding; rarely photosensitivity; increased risk in breast cancer; elevation of plasma bound iodine, cortisol and thyroid binding, erythrocyte sedimentation may be accelerated; increases in plasma copper, iron and alkaline phosphatase; may affect serum triglyceride and lipoprotein levels; retinal vascular thrombosis.
Potentially Fatal: Hepatic tumours; increased risk of thromboembolism.
Ethinylestradiol contraindications
Estrogens should not be used in individuals with any of the following conditions:
1. Undiagnosed abnormal genital bleeding.
2. Known, suspected, or history of cancer of the breast.
3. Known or suspected estrogen-dependent neoplasia
4. Active deep vein thrombosis, pulmonary embolism, or history of these conditions.
5. Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).
6. Liver dysfunction or disease.
7. EstroGel therapy should not be used in patients with known hypersensitivity to its ingredients.
8. Known or suspected pregnancy. There is no indication for EstroGel in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy.
Active ingredient matches for Ethinylestradiol:
Ethinylestradiol
| Unit description / dosage (Manufacturer) | Price, USD |
| Dragee; Oral; Ethinyl Estradiol 0.025 mg | |
List of Ethinylestradiol substitutes (brand and generic names): | |
| Ethinyl-Oestradiol Effik (France) | |
| Ethinylestradiol IBSA (Malta) | |
| Ethinylestradiol Jenapharm (Germany) | |
| Ethinylestradiol UCB (United Kingdom) | |
| Ethinyloestradiol (New Zealand) | |
| Tablet; Oral; Ethinyl Estradiol 0.05 mg | |
| Tablet; Oral; Ethinyl Estradiol 0.01 mg | |
| Tablet; Oral; Ethinyl Estradiol 1 mg | |
| Ethinyloestradiol Effik (France) | |
| Ethinyloestradiol New Zealand Medical & Scientific (New Zealand) | |
| Ethynyl Estradiol - AR 0.5 mg | |
| Etinilestradiol L.CH. (Chile) | |
| Etinilestradiolo Amsa (Italy, Malta) | |
| Etinylestradiolo Ibsa (Italy) | |
| Evecontra (India) | |
| Evecontra Drospirenone 3 mg, Ethinylestradiol 30 mcg. TAB / 28 (Amra (Womencare)) | $ 3.37 |
| EVECONTRA tab 28's (Amra (Womencare)) | $ 3.37 |
| Femodene (Belgium, Georgia, Luxembourg, South Africa, United Kingdom) | |
| Tablet, Sugar-Coated; Oral; Ethinyl Estradiol 0.03 mg; Gestodene 0.075 mg (Bayer) | |
| Gestadene (Switzerland) | |
| Ginette 35 | |
| Ginette 35 Ethinyl Estradiol 0.035mg, Cyproterone Acetate 2mg, 21yellow coloured active filmcoated tablets and 7 whitecoloured placebo film KIT / 28 | $ 2.36 |
| Ginette 35 Ethinyl Estradiol 0.035mg, Cyproterone Acetate 2mg, 21yellow coloured active filmcoated tablets and 7 whitecoloured placebo film KIT / 21 | $ 2.52 |
| Ginette 35 Tablet (Cipla Ltd) | $ 0.16 |
| Gynofen-35 (Greece) | |
| Lenest 20 ED (Australia) | |
| LOCIPIL (India) | |
| 21's (Corona (Aarush)) | $ 1.14 |
| Locipil Ethinylestradiol 0.02 mg, Desogestrel 0.15 mg. TAB / 21 (Corona (Aarush)) | $ 1.42 |
| LOCIPIL 0.03 MG/0.15 MG TABLET 1 strip / 21 tablets each (Corona (Aarush)) | $ 1.81 |
| LOCIPIL tab 21's (Corona (Aarush)) | $ 1.69 |
| Locipil Ethinylestradiol 0.02 mg, Desogestrel 0.15 mg. TAB / 21 (Corona (Aarush)) | $ 1.42 |
| Locipil 0.03 mg/0.15 mg Tablet (Corona (Aarush)) | $ 0.09 |
| Lusia F | |
| Lusia F Norgestrel 0.3mg, EthinylEstradiol 0.03mg, Fe Fumerate75mg TAB / 28 | |
| Lynoral (India, Indonesia, Netherlands, Sri Lanka) | |
| Tablet; Oral; Ethinyl Estradiol 0.01 mg (Organon) | |
| Tablet; Oral; Ethinyl Estradiol 0.05 mg (Organon) | |
| LYNORAL Capsule/ Tablet / 0.05mg / 10 units (Organon) | $ 0.59 |
| LYNORAL Capsule/ Tablet / 1mg / 10 units (Organon) | $ 0.31 |
| LYNORAL Capsule/ Tablet / 0.01mg / 10 units (Organon) | $ 0.40 |
| Lynoral 50 mcg x 100's (Organon) | $ 16.58 |
| Lynoral 0.01mg TAB / 10 (Organon) | $ 0.41 |
| Lynoral 0.05mg TAB / 10 (Organon) | $ 0.22 |
| Lynoral 1mg TAB / 10 (Organon) | $ 0.31 |
| 0.01 mg x 10's (Organon) | $ 0.41 |
| 0.05 mg x 10's (Organon) | $ 0.22 |
| 1 mg x 10's (Organon) | $ 0.31 |
| LYNORAL 0.01 MG TABLET 1 strip / 10 tablets each (Organon) | $ 0.27 |
See 96 substitutes for Ethinylestradiol | |
Reviews
The results of a survey conducted on ndrugs.com for Ethinylestradiol are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ethinylestradiol. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
